6.30 +0.05 (0.80%)
After hours: 7:48PM EST
|Bid||6.30 x 1000|
|Ask||6.36 x 800|
|Day's Range||6.22 - 6.75|
|52 Week Range||5.01 - 41.36|
|Beta (3Y Monthly)||3.59|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 7, 2017 - Aug 11, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||39.83|
HENDERSON, NV / ACCESSWIRE / January 10, 2019 / Biotech has started 2019 off with a bang. Below are a few that you should be paying attention to. One that looks poised for a big year, Delcath Systems, ...
La Jolla Pharmaceutical Company (NASDAQ: LJPC ) reported net 2018 sales of $10.1 million for the septic shock treatment Giapreza this week and announced 2019 sales guidance of $24 million to $28 million ...
La Jolla's share price fell to $5.64 by 2:34 pm, down from its close of $10.52 on Friday, after the company said it expects sales of low blood pressure drug Giapreza to hit $24 million-$28 million in 2019, roughly half of what analysts had projected. The pharmaceutical company's stock has been trending downward since late September, when it was trading at more than $22. La Jolla reported a 20% increase during the fourth quarter in sales of Giapreza, first launched in March, with sales of the drug, used to increase blood pressure in patients suffering from septic or distributive shock.
Shares of La Jolla Pharmaceutical Co. plummeted 44% in midday trade Monday to pace all Nasdaq losers, after the company provided downbeat guidance on its key drug that treats dangerously low blood pressure in adults with septic or other disruptive shock. The company said its fourth-quarter sales of Giapreza, which was launched in March 2018, rose 20% from a year ago to $4.2 million, with 2018 sales expected to reach $10.1 million. The Giapreza sales estimates of the two analysts that provided estimates to FactSet ranged from $5.2 million to $6.9 million for the fourth quarter and $11.1 million to $12.8 million for 2018. For 2019, La Jolla Pharmaceuticals said it expects Giapreza sales to rise to $24 million to $28 million, while analyst estimates ranged from $44.3 million to $55.0 million. The stock, on track for the lowest close since September 2013, has now plummeted 68% over the past three months, while the S&P 500 has declined 11%.
- Fourth-Quarter 2018 Net Sales of GIAPREZA Were Approximately $4.2 Million, Up 20% from the Third Quarter of 2018 - - Full-Year 2019 Net Sales Guidance for GIAPREZA of $24.
SAN DIEGO, Jan. 04, 2019 -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to.
There are several ways to beat the market, and investing in small cap stocks has historically been one of them. We like to improve the odds of beating the market further by examining what famous hedge fund operators such as Carl Icahn and George Soros think. Those hedge fund operators make billions of dollars each […]
NEW YORK, Nov. 06, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
CORAL GABLES, FL / ACCESSWIRE / October 25,2018 / Healthcare stocks have helped to boost the US equity markets today. The Select Sector SPDR Healthcare ETF (XLV) has had a strong recovery on Thursday and the broader markets are also surging. The healthcare industry has seen a shakeup recently as new technology innovation and further research on new drugs pushes industry margins.
La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of 3.98% and 2.82%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The San Diego-based company said it had a loss of $1.93 per share. The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss ...
SAN DIEGO, Oct. 24, 2018 -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 23) Amarin Corporation plc (NASDAQ: AMRN ) Imprimis Pharmaceuticals ...
Anyone researching La Jolla Pharmaceutical Company (NASDAQ:LJPC) might want to consider the historical volatility of the share price. Modern finance theory considers volatility to be a measure of risk, and Read More...
La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of -5.76% and -35.64%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
The San Diego-based company said it had a loss of $2.02 per share. The results fell short of Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for ...
NEW YORK, NY / ACCESSWIRE / August 8, 2018 / La Jolla Pharmaceutical Company (NASDAQ: LJPC ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 8, 2018 at 4:30:00 ...